Source: Quotient Bioresearch Limited
Wednesday, December 02, 2009
30 November 2009, Fordham, Cambridgeshire, UK: At the upcoming European Bioanalysis Forum, Barcelona, 2-4 Dec 2009, Quotient Bioresearch will feature two significant pieces of recent work. In the posters presented, Quotient experts will pick up on the themes of this year’s event - new and improved methods and methodologies, emerging guidelines, and quality and validation in biomarkers and bioanalysis. In addition, as a gold-level sponsor of the conference, members of Quotient’s scientific team will be on Booth 11 to discuss how the company can help with small molecule bioanalysis for both discovery and regulatory projects, and answer questions about method development services.
advertisement
Dr David Griffiths, Business Development Director at Quotient Bioresearch said: “More than 40 years experience in the field of biomarkers and bioanalysis gives Quotient a unique place in the market. The company is a leading specialist in the analysis of small molecule drugs in biological fluids and has particular strength in mass spectrometry. Quotient has long been at the forefront of the biomarker revolution. Now, as more clinical programmes rely on the insight that these methods deliver, our experience and know-how are making a major contribution to drug discovery and development.”
Poster 1:
Validation of an immunoassay for the determination of leukotriene B4 in human sputum supernatant
An assessment - and validation to GLP regulations - of a competitive immunoassay for the determination of leukotriene B4 (LTB4) in human spontaneous sputum supernatant from bronchiectasis patients is reported in this poster. LTB4 is a potent inflammatory mediator which stimulates leukocyte functions including aggregation and chemotaxis. It is considered a good biomarker for respiratory diseases.
Poster 2:
An approach to avoiding phospholipid-based matrix effects in LC-MS/MS assays
Matrix effects can lead to inconsistency and reduced accuracy and sensitivity in LC-MS/MS bioanalysis. Phospholipids, particularly glycerophosphocholines (GPCho), are abundant in plasma and are a significant cause of these effects. Quotient analyzed a range of small molecule drugs using UPLC-MS/MS. Retention time data were used to create LC prediction equations. In addition, the capacity to remove GPCho phospholipids for a range of different extraction techniques was investigated. The models generated from this work have many potential benefits and look set to significantly speed up the process of LC-MS/MS method development.
For more details about Quotient’s unique range of drug development services – for biologics as well as small molecules – visit: www.quotientbioresearch.com
About Quotient Bioresearch
Quotient is a leading provider of drug development services with a focus on early-stage drug development services. The Company offers a unique range of drug development services through its three principal operating units – Quotient Radiochemistry & Metabolism, Quotient Bioanalytical Sciences (including Microbiology) and Quotient Clinical. Quotient has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Quotient Bioresearch is part of Quotient Bioscience Group, which comprises Quotient Bioresearch, HFL Sport Science and Quotient Biodiagnostics.
For further information: www.quotientbioresearch.com
Media Contacts:
David Griffiths, Business Development Director, Quotient Bioresearch
+44 (0)1638 720 500
Richard Kent, Director, Kapler Communications
+44 (0)1480 479 280